Phaseline

Companies › Beijing Zhifei Lvzhu Biopharmaceutical

Beijing Zhifei Lvzhu Biopharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 3; Other, Infectious disease; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
23 Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
Polysaccharide vaccine containing capsular polysaccharides from 23 Streptococcus pneumonia
–Phase 3Healthy VolunteersJun 2028
S. Flexneri-S. Sonnei bivalent conjugate vaccine
Conjugate vaccine against Shigella flexneri and Shigella sonnei
–Phase 3DysenteryJul 2028
Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorb
DTaP vaccine - inactivated toxoids and acellular pertussis antigens
–Phase 3Healthy VolunteersDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0631486723 Valent Pneumococcal Polysaccharide Vaccine (PPSV23)Phase 3Healthy VolunteersOtherJun 2028
NCT06838195S. Flexneri-S. Sonnei bivalent conjugate vaccinePhase 3DysenteryInfectious diseaseJul 2028
NCT06344065Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbPhase 3Healthy VolunteersOtherDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical ULURU

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.